Dostarlimab and new treatments for advanced endometrial cancer before surgery
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests the drug dostarlimab, alone or with other therapies, given before surgery in people with advanced stage 3 or 4 endometrial cancer. The goal is to see if these treatments shrink the cancer and improve outcomes before the planned operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage 3 or 4 endometrial cancer that can be removed with surgery.
- You have not had any cancer treatment (like chemo, radiation, or hormones) for this cancer before.
- Your tumor is a type called epithelial endometrial cancer (not carcinosarcoma).
- You are willing to give a tissue sample from a previous biopsy and allow new samples during the study.
- Your cancer's mismatch repair status (a genetic marker) is known and you have either deficient mismatch repair or high microsatellite instability.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding dostarlimab (an immunotherapy medicine) to radiation after surgery can lower cancer returning and improve outcomes. It’s for people with certain endometrial cancers found to have specific genetic/molecular changes and who have stage III/IVA disease after surgery.
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
This trial tests a drug called dostarlimab (an immunotherapy) given before surgery for early-stage endometrial cancer that has a specific genetic feature (MMRd/MSI-H). The goal is to see if the drug can shrink or eliminate the cancer before standard surgery.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This study tests a drug called dostarlimab for people in India whose endometrial cancer has come back or spread and has a specific genetic profile (dMMR/MSI-H). It may be an option if platinum-based chemotherapy stopped working.
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.